SOLID TUMORS

This early-phase study tested a new type of cell therapy (CAR-T cells) designed to attack tumors that have a protein called ALPP. Five adults with advanced solid tumors that had no standard treatment options received the therapy. The main goals were to check safety and see if the…

This early-phase study tested an experimental drug (MK-1454) given as a shot into tumors, either alone or with the immunotherapy pembrolizumab, in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study…

This early-phase study tested a new drug called DF6002, given alone or with the immunotherapy nivolumab, in 170 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug shri…

This early-phase study tested a combination of two drugs, dasatinib and bevacizumab, in 50 adults with advanced solid tumors that no longer responded to standard treatments. The goal was to find the safest doses and see how the drugs affected the cancer and the body. Participants…

This early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a standard chemo drug) could safely treat advanced solid tumors that had stopped responding to other therapies. 47 adults and children aged 12 and older took part. The goal was to find the safest dose …

This early-phase trial tested a new drug called RS-0139 in 16 adults with advanced solid tumors that had come back or spread. The main goal was to find the best dose and check for side effects. Researchers also looked at whether the drug could shrink tumors or slow cancer growth.

This early-phase trial tested a drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if TdCyd is safe and can help turn back on genes that slow tumor growth. Participants took the drug in 3-week cycles a…

This early-phase study tested whether immune cells called natural killer (NK) cells, taken from the patient's own blood and boosted in a lab, could be safely given back to children and young adults with solid tumors that didn't respond to standard treatments. Sixteen participants…

This early-phase trial tested a combination of immune cells (cellular immunotherapy) in 9 people with stage IV solid tumors that had not responded to standard treatments. The main goal was to check safety and side effects, while also looking at whether the therapy could shrink tu…

This early-phase study tested a new drug called eciskafusp alfa, alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose. Researcher…

This study tested an experimental drug called IDX-1197 in 108 adults with solid tumors that have a specific gene mutation (HRR). Participants had already tried standard treatments without success. The goal was to find the safest and most effective dose and see if the drug could s…

This study tested a drug called bemarituzumab in 260 people with solid tumors that have too much of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This early-phase study tested a drug called revumenib in 42 adults with colorectal cancer or other solid tumors that had worsened after at least one prior treatment. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors or slow cancer g…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow their growth. While not a cure, the drug …

This early-stage study tested a new drug called CFT1946 in 89 adults with advanced solid tumors that have a specific BRAF V600 gene change. The goal was to find safe doses and see if the drug, given alone or with other medicines, can shrink tumors. The study focused on safety and…

This study observed 225 adults with solid tumors who received G-CSF (a drug to boost white blood cells) during chemotherapy, which often causes bone pain. Researchers tracked pain levels, quality of life, and which pain relief methods (like medications or non-drug approaches) wer…

This study looked at whether taking statins, a common cholesterol medicine, can lower the risk of hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect…

This study tested whether iPhones and Apple Watches can help monitor symptoms and activity levels in people with cancer. 49 adults receiving cancer treatment at the NIH wore an Apple Watch and used an iPhone for 4 months. The goal was to see if these devices could reliably measur…

This study in France looked at how satisfied cancer patients were when they switched from getting immunotherapy in the hospital to getting it at home. It included 49 adults with solid tumors. Researchers used a questionnaire to measure changes in satisfaction. The goal was to und…

This study looked at how a new cancer drug (BI 907828) interacts with two common medicines: rifampicin (an antibiotic) and itraconazole (an antifungal). Thirty-three adults with advanced solid tumors who had run out of other options took part. Researchers measured drug levels in …

This study tested tumor samples from 470 people with solid tumors to look for specific biomarkers. The goal was to see if those biomarkers could make them eligible for other Roche clinical trials. No treatment was given in this study—it was purely a screening step to help match p…

This early-phase study looked at how the cancer drug belinostat is processed in the body based on a person's UGT1A1 gene type. Seventeen adults with advanced solid tumors or blood cancers that had come back or stopped responding to treatment took part. The goal was to measure dru…

This study tested whether a computer could learn to recognize cancer pain by analyzing people's facial expressions and voices. 83 people with cancer recorded short videos at the clinic and at home over three months. The goal was to see if this technology could be a useful tool fo…